COMMUNIQUÉS West-GlobeNewswire

KFSH Forecasts Emergency Demand 24 Hours Ahead with AI as Time to See a Physician Falls 42%
21/10/2026
RIYADH, Saudi Arabia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is using artificial intelligence to forecast Emergency Department demand 24 hours ahead, double its [...]
NRG Therapeutics Announces a PET Biodistribution Trial of Lead Clinical Asset NRG5051
21/10/2026
STEVENAGE, United Kingdom, Oct. 21, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in [...]
Promising Early Safety Data as Quell Therapeutics Advances QEL-005 – a Novel Engineered nTreg Therapy – to Second Dose Cohort in CHILL Phase 1/2 Trial in Difficult-to-Treat Rheumatoid Arthritis and Systemic Sclerosis
21/10/2026
Safe completion of the first dose cohort in which QEL-005 was well tolerated, with no dose-limiting toxicities (DLTs), no treatment-related adverse events of special interest (AESIs) and no serious adverse events (SAEs [...]
Vistin Pharma ASA: Invitation to Q3 2026 conference call
21/10/2026
Oslo, Norway, 21 October 2026 Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2026 results on Thursday 29th of October 2026. Vistin Pharma will host a conference call for all shareholders and interested [...]
F2G and Shionogi Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome® Followed by Standard of Care in Invasive Aspergillosis in Late-Breaking Oral Presentation at IDWeek 2026
21/10/2026
Oral olorofim was non-inferior to AmBisome ® followed by standard of care (AmBisome ® +SOC), with Day 42 all-cause mortality of 23.8% for olorofim versus 24.3% for AmBisome ® +SOC in patients with invasive aspergillosis [...]
Premier patient traité dans le cadre de l’essai clinique C-FLASH-01 sur ConformalFLASH®
21/10/2026
Premier patient traité dans le cadre de l’essai clinique C-FLASH-01 sur ConformalFLASH ® Louvain-la-Neuve, Belgique, le 21 octobre 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’ [...]
First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial
21/10/2026
First Patient Treated in the C-FLASH-01 ConformalFLASH ® Clinical Trial Louvain-la-Neuve, Belgium, October 21, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and [...]
ONWARD Medical Announces the Appointment of Fouad Azzam to its Board of Directors
21/10/2026
Fouad Azzam is a Partner with EQT Life Sciences, bringing extensive experience investing in and supporting fast-growing medical technology and life sciences companies EINDHOVEN, the Netherlands, Oct. 21, 2026 (GLOBE [...]
Kylo Peptides Marks Record Month as Brand Searches Nearly Triple
21/10/2026
Sheridan, Wyoming, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ], a research peptide supplier, recorded its highest month of brand search interest in September 2026. Estimated US searches [...]
Avance Clinical to Meet European Biotechs at ESMO Congress 2026 and Appoints Wendy Hamon as Senior Vice President, Oncology Center of Excellence
21/10/2026
Executive Medical Director Dr George Peoples to discuss oncology programs from preclinical through Phase II in Madrid ADELAIDE, Australia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global full-service CRO [...]
Bioxodes BIOX-101 Phase 2a data show statistically significant reduction in perihematomal edema growth in intracerebral hemorrhage
21/10/2026
First disclosure of new imaging analyses and one-year functional outcome were presented at the World Stroke Congress today Change in normalized hemorrhage volume was significantly lower with BIOX-101 versus standard of [...]
Teknova Announces Pricing of $40 Million Public Offering of Common Stock
21/10/2026
HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
20/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 20. Oct 2026 / 23:54 CET/CEST, transmitted by [...]
Telix Reports Third Quarter 2026 Financial Performance
21/10/2026
MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the [...]
Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
21/10/2026
ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development [...]
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
21/10/2026
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on [...]
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
21/10/2026
WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments [...]
Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies
20/10/2026
Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to support clinical pharmacology characterization across pipeline programs NEW YORK, Oct. 20, 2026 ( [...]
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
20/10/2026
WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti- [...]

Pages